Acarix AB ACARIX
OMXSTO · Sweden · Health Technology
SEK 0.2115+0.02 (+9.13%)
Market closed· · SEK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · SEK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Acarix AB (publ) today announced the publication of a peer-reviewed study in PLOS Digital Health showing that the seismocardiography (SCG) technology at the heart of its CE-marked, FDA-cleared CADScor®System can also detect heart failure (HF), a condition distinct from the coronary artery disease (CAD) the device is currently indicated for.
Acarix AB (ACIXF) reports robust Q2 2026 results with US revenue up 223%, UAE market entry, and key progress toward CPT1 reimbursement transition.
Acarix will launch the CADScor system in the UAE through UniTech Solutions, which will manage regional distribution.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.